Business Context and Reporting Period
This Form 8-K Current Report was filed by Cytosorbents Corp on September 16, 2019, covering events occurring on September 10, 2019. The filing serves as a Regulation FD disclosure regarding a presentation made by the Company's President and CEO, Dr. Phillip P. Chan, at the H.C. Wainwright 21st Annual Global Investment Conference.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation and does not contain audited financial statements or quarterly results.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The document solely references the delivery of an overview presentation to investors.
Guidance, Outlook, and Risks
Management commentary is limited to the fact that an overview of the Company was presented at the conference. The filing explicitly states that the presentation slides (Exhibit 99.1) and the information in Item 7.01 are not deemed "filed" for purposes of Section 18 of the Exchange Act and are not subject to its liabilities unless specifically incorporated by reference. No specific guidance, risks, or contingencies are enumerated in the text.
Investor Verification Checklist
- Verify the content of the presentation slides attached as Exhibit 99.1 for any forward-looking statements or strategic updates.
- Confirm whether the presentation materials have been incorporated by reference into other filings to determine their legal status under the Exchange Act.
- Review the Company's most recent 10-Q or 10-K for actual financial performance metrics, as this 8-K does not contain them.